https://www.selleckchem.com/pr....oducts/Pitavastatin-
Background This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials methods A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and
Like
Comment
Share
